Paul Hastings Advised ACELYRIN On Its Merger With Alumis Inc.

Paul Hastings advised ACELYRIN on its merger with Alumis Inc.

Paul Hastings LLP advised ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharmaceutical company focused on accelerating the development and delivery of transformative medicines in immunology, on its merger agreement with Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases.

The Paul Hastings team was led by Eduardo Gallardo (Global Co-Chair, Mergers & Acquisitions), with support from Sean Donahue (Partner) and Andrew Goodman (Partner).

Click to know more about Paul Hastings

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.